Cite
HARVARD Citation
Zinzani, P. et al. (n.d.). Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B‐cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE‐170 phase 2 trial. Hematological oncology. pp. 62-63. [Online].